News

Financial details of the transaction have not been disclosed. The partnership aims to deliver durable weight loss with improved tolerability, focusing on a target and modality of established

The post InterAx and Alveus collaborate on small-molecule metabolic treatment appeared first on Pharmaceutical Business review.

The collaboration secures funding and sustained biologics manufacturing capacity in the US for Agenus, supporting clinical development, early access initiatives, and future commercial production. Under the agreement, Agenus

The post Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal appeared first on Pharmaceutical Business review.

The company aims to strengthen the pharmaceutical supply chain and accelerate the delivery of biologic and glucagon-like peptide-1 (GLP-1) drugs. BD will introduce Neopak Glass Prefillable Syringe manufacturing

The post BD invests $110m to expand US prefillable syringe production appeared first on Pharmaceutical Business review.

Menkes disease is a rare X-linked recessive disorder caused by mutations in the ATP7A gene, resulting in impaired copper absorption and transport. Zycubo is administered subcutaneously to restore

The post Fortress Biotech receives FDA approval for Zycubo to treat Menkes disease appeared first on Pharmaceutical Business review.

The agreement will leverage SciNeuro’s proprietary blood-brain barrier shuttle technology, aiming to deliver potential differentiation from current amyloid beta agents in development or on the market. Both companies

The post SciNeuro and Novartis sign global licensing deal for Alzheimer’s antibody appeared first on Pharmaceutical Business review.

The application sought approval for Ebvallo as monotherapy in adult and paediatric patients aged two years and above with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have

The post Atara receives FDA complete response letter for Ebvallo BLA application appeared first on Pharmaceutical Business review.

The facility forms a key component of the company’s $23bn US investment programme, first outlined in April 2025, and aims to enhance the supply of RLT cancer treatments

The post Novartis to build fourth US radioligand therapy facility in Florida appeared first on Pharmaceutical Business review.

Under the agreement, MediLink will receive upfront and near-term milestone payments totalling $570m. Additional development, regulatory, and commercial milestone payments are included in the deal, along with tiered

The post MediLink and Roche announce exclusive licensing agreement for YL201c appeared first on Pharmaceutical Business review.

Through this partnership, Takeda aims to enhance patient care while exploring new opportunities for vedolizumab. Marketed as Entyvio, vedolizumab is approved for adults with moderately to severely active

The post Takeda and Halozyme sign global agreement for Enhanze technology appeared first on Pharmaceutical Business review.

Agamree is a new drug that operates by attaching to the same receptor as glucocorticoids while altering its downstream activity. The agreement involves the development, manufacturing and commercialisation

The post Santhera grants Agamree rights to Nxera for DMD appeared first on Pharmaceutical Business review.